FDA Clearance Tracker · P170008
EluNIR Ridaforolimus Eluting Coronary Stent System
Last checked: Nov 20, 2026Latest source record: Nov 28, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Nov 28, 2017
Approved
Time to decision
260 days
Received Mar 13, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P170008
- Device name
- EluNIR Ridaforolimus Eluting Coronary Stent System
- Applicant
- Medinol, Ltd.
- Applicant location
- Tel Aviv
- Received
- Mar 13, 2017
- Decided
- Nov 28, 2017
- Decision
- Approved
- Supplements
- 54 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Coronary drug-eluting stent (NIQ)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the EluNIR Ridaforolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo lesions <=30mm in length in native coronary arteries with reference diameter of 2.50mm to 4.25mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NIQ. The earliest in FDA's data is P020026, decided Apr 24, 2003.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Medinol, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K173581 · Decided Jan 25, 2018 · 66 days after receipt
Device type: Catheters, Transluminal Coronary Angioplasty, Percutaneous (LOX) · Cardiology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.